Who Benefits the Most From Adjuvant Durvalumab After Chemoradiotherapy for Non-small Cell Lung Cancer? An Exploratory Analysis.
Pract Radiat Oncol
; 11(2): e172-e179, 2021.
Article
in En
| MEDLINE
| ID: mdl-33127337
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Carcinoma, Non-Small-Cell Lung
/
Lung Neoplasms
Type of study:
Prognostic_studies
Limits:
Humans
Language:
En
Journal:
Pract Radiat Oncol
Year:
2021
Document type:
Article